Drugs / COR-1167
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06815471 | Aug 2025 → Dec 2026 expected | symptomatic heart failure | Corteria Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COR-1167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06815471 ↗ |
| Action | Activate | “the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167” NCT06815471 ↗ |
| Modality | Peptide | “the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167” NCT06815471 ↗ |